Janus Henderson Group PLC Sells 5,562,370 Shares of Pfizer Inc. $PFE

Janus Henderson Group PLC trimmed its position in Pfizer Inc. (NYSE:PFE) by 63.3% in the first quarter, Holdings Channel.com reports. The firm owned 3,223,714 shares of the biopharmaceutical company’s stock after selling 5,562,370 shares during the period. Janus Henderson Group PLC’s holdings in Pfizer were worth $90,506,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in PFE. Norges Bank bought a new stake in Pfizer in the fourth quarter valued at about $1,830,986,000. Morgan Stanley boosted its holdings in Pfizer by 19.2% during the fourth quarter. Morgan Stanley now owns 89,113,604 shares of the biopharmaceutical company’s stock worth $2,218,929,000 after buying an additional 14,342,946 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Pfizer by 38.9% during the 4th quarter. Bank of New York Mellon Corp now owns 48,514,971 shares of the biopharmaceutical company’s stock worth $1,208,023,000 after buying an additional 13,581,757 shares during the period. Capital World Investors increased its stake in shares of Pfizer by 51.5% in the 4th quarter. Capital World Investors now owns 21,433,890 shares of the biopharmaceutical company’s stock valued at $533,704,000 after acquiring an additional 7,287,194 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of Pfizer by 1.3% in the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock valued at $13,479,520,000 after acquiring an additional 7,031,162 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of NYSE PFE opened at $25.10 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The stock has a 50 day moving average price of $25.04 and a 200 day moving average price of $26.15. The stock has a market capitalization of $143.06 billion, a PE ratio of 19.16 and a beta of 0.35. Pfizer Inc. has a 52 week low of $23.11 and a 52 week high of $28.75.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion for the quarter, compared to analysts’ expectations of $13.84 billion. During the same quarter in the prior year, the business posted $0.92 EPS. The business’s revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be paid a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. Pfizer’s dividend payout ratio (DPR) is currently 131.30%.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Positive Phase 3 vitiligo data: Pfizer reported that oral LITFULO significantly improved skin repigmentation in two late-stage trials for nonsegmental vitiligo. The results support planned regulatory filings and could create a new growth opportunity for the company. Reuters LITFULO vitiligo trial article
• Positive Sentiment: Updated COVID vaccine approved in Europe: The European Commission authorized Pfizer and BioNTech’s XFG-adapted vaccine for the 2026–2027 season across the European Union. The approval enables production and advance supply, although seasonal COVID demand remains difficult to forecast. EU approval article
• Positive Sentiment: Value appeal and estimates: Investor commentary highlights Pfizer’s roughly 6.8% dividend yield and inexpensive earnings valuation, while Erste Group reportedly raised its FY2027 EPS estimate. These factors may attract income and value-focused investors. Pfizer valuation article
• Neutral Sentiment: Upcoming earnings focus: Analysts are watching Pfizer’s second-quarter revenue, adjusted earnings, product sales and full-year outlook. The available reports are previews rather than an announcement of actual quarterly results, so earnings remain a near-term catalyst. Pfizer Q2 earnings preview
• Negative Sentiment: Growth concerns remain: Pfizer’s valuation reflects investor skepticism about post-pandemic revenue, a comparatively modest growth profile and execution risks surrounding its pipeline. Its obesity-drug candidate is promising but still late-stage and faces powerful competition from Eli Lilly and Novo Nordisk, limiting any immediate earnings benefit. Pfizer earnings preview and valuation article

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the stock. UBS Group reissued a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research note on Wednesday, May 27th. JPMorgan Chase & Co. cut their target price on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a report on Wednesday, July 8th. HSBC cut shares of Pfizer from a “buy” rating to a “hold” rating and reduced their price target for the stock from $32.00 to $28.00 in a research report on Monday, July 6th. BMO Capital Markets decreased their price target on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Finally, Morgan Stanley boosted their target price on Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, Pfizer currently has an average rating of “Hold” and a consensus target price of $28.50.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.